https://doi.org/10.1056/NEJMoa2517729
1h ago
Source
bskyhttps://doi.org/10.1056/NEJMoa2517729doi.orgZanidatamab, a bispecific HER2 antibody, plus chemo, with/without Tislelizumab, shows efficacy in phase 2/3 trials for HER2+ gastroesophageal cancer! PMID:42202319, N Engl J Med 2026, @NEJM #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
You might also wanna read
Support Amy Grech
ko-fi.com·1h agoAggrieved German supporters jeer Spain's Marc Cucurella during Euro 2024 semifinal vs. France
apnews.com·1h ago
Sources: Grizzlies trading star Ja Morant to Trail Blazers
espn.com·1h ago
Developing Guidelines for working with Multi-Model Ensembles in CMIP
esd.copernicus.org·1h ago
The computational and energy cost of simulation and storage for climate science: lessons from CMIP6
gmd.copernicus.org·1h ago
Kraken vs Bruins Shootout Thriller! 🚨🥶
lovenhl.com·1h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.